1. Home
  2. PRME vs NRIM Comparison

PRME vs NRIM Comparison

Compare PRME & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

NRIM

Northrim BanCorp Inc

SELL

Current Price

$23.44

Market Cap

531.6M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
NRIM
Founded
2019
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
531.6M
IPO Year
2022
2002

Fundamental Metrics

Financial Performance
Metric
PRME
NRIM
Price
$4.23
$23.44
Analyst Decision
Buy
Buy
Analyst Count
13
3
Target Price
$7.03
★ $28.33
AVG Volume (30 Days)
★ 5.5M
123.5K
Earning Date
11-12-2026
10-15-2026
Dividend Yield
N/A
★ 2.84%
EPS Growth
★ 18.18
N/A
EPS
N/A
★ 1.92
Revenue
$4,632,000.00
★ $255,581,000.00
Revenue This Year
$18.58
$1.76
Revenue Next Year
$23.34
$25.33
P/E Ratio
★ N/A
$12.47
Revenue Growth
★ 55.28
30.43
52 Week Low
$2.67
$21.94
52 Week High
$5.91
$30.82

Technical Indicators

Market Signals
Indicator
PRME
NRIM
Relative Strength Index (RSI) 51.32 41.37
Support Level $2.94 $23.42
Resistance Level $4.80 $25.33
Average True Range (ATR) 0.53 0.62
MACD -0.08 0.02
Stochastic Oscillator 22.25 6.65

Price Performance

Historical Comparison
PRME
NRIM

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About NRIM Northrim BanCorp Inc

Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.

Share on Social Networks: